The European Medicine Agency (EMA) has conditionally approved the use of Corona pill by US multinational biotechnology firm Pfizer for the treatment of adults at risk of serious illness. According to a report by the Xinhua news agency, the approval of EU member states allowed the use of the drug after the EMA issued guidelines for its emergency use late last year.
The EMA said in a statement that “the Committee for the Use of Medicinal Products (CHMP) had recommended marketing authority for the treatment of corona in adults with the condition for the antiviral drug Pixlovid.” , Who do not need alternative oxygen and who are at serious risk. “
Pixlovid is the first antiviral drug to treat corona in the European Union. It contains two active ingredients packed together. One reduces the multiplication of SARS-CoV-2 in the body, while the other enables the first thing to stay in the body longer at levels that affect the multiplication of the virus.
The EMA said it reviewed data from a study of coronary artery disease patients, which found that treatment with Paxlovid increased the risk of hospitalization and death in patients with at least one critical condition. Reduced significantly. Most of the patients in the study were infected with a delta variant of the corona virus. Based on laboratory research, Pixlovid is also expected to be effective against omecron and other forms. The EMA said the side effects of the pill were extremely mild. The EMA’s recommendation was sent to the European Commission for immediate decision to be implemented in all EU member states.